Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00067158
First received: August 12, 2003
Last updated: April 13, 2010
Last verified: April 2010
  Purpose

The purpose of this study is to look at how feasible it is to incorporate a state-of-the-art smoking cessation treatment program into community substance abuse treatment programs and its impact on substance abuse and cigarette smoking.


Condition Intervention Phase
Tobacco Use Disorder
Drug: nicotine transdermal system
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Smoking Cessation

Estimated Enrollment: 585
Study Start Date: April 2003
Study Completion Date: July 2004
Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is alcohol or drug dependent, in Outpatient Drug-Free or Opiate Substitute program and is interested in quitting smoking

Exclusion Criteria:

  • Patient is psychotic
  • Use of smokeless tobacco
  • Use of other smoking cessasation product
  • Pregnancy
  • Patient has hyper-tension, heart problems, or skin condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067158

Locations
United States, California
Matrix Institute on Addictions
Los Angeles, California, United States, 90016
Tarzana Treatment Center
Tarzana, California, United States, 91356
United States, Florida
SPECTRUM
Miami, Florida, United States, 33156
Center for Drug Free Living
Orlando, Florida, United States, 32805
United States, Michigan
Chelsea Arbor Addictions Treatment Center
Ann Arbor, Michigan, United States, 48103
Psychiatry and Behavioral Medicine Professionals I
Detroit, Michigan, United States, 48207
United States, New York
Narco Freedom (Bridge Plaza)
Long Island City, New York, United States, 11101
St. Luke's Roosevelt Hospital Center, Womens
New York, New York, United States, 10025
St. Luke's Roosevelt Hospital Center
New York, New York, United States, 10019
Mount Sinai Medical Center
New York, New York, United States, 10029
United States, North Carolina
Piedmont Behavioral Healthcare
Concord, North Carolina, United States, 28001
Coastal Horizons Center, Inc.
Wilmington, North Carolina, United States, 28412
United States, South Carolina
Behavioral Health Services of Pickens County
Pickens, South Carolina, United States, 29671
Sponsors and Collaborators
New York University
Investigators
Principal Investigator: Malcolm Reid, Ph.D. New York University
  More Information

No publications provided

Responsible Party: Malcome Reid, Ph.D., New York University
ClinicalTrials.gov Identifier: NCT00067158     History of Changes
Other Study ID Numbers: NIDA-CTN-0009-1
Study First Received: August 12, 2003
Last Updated: April 13, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Tobacco Use Disorder
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Nicotine
Autonomic Agents
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 29, 2014